Discover trends, market shifts, and competitive outlooks for the afluria global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Has the Afluria Market Growth Performance Trended Historically, And What Lies Ahead?
The market size of Afluria has experienced a health compound annual growth rate (HCAGR) of XX in the recent past. The market is projected to expand from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. Reasons for this growth during the historic periods include a rise in flu cases, an aging population, escalating healthcare costs, growing consciousness about vaccine safety, and an uptick in public health campaigns.
Predictions for the Afluria market indicate a growth of XX (FCAGR) in the forthcoming years. It’s projected to reach a valuation of $XX million in 2029, with a compound annual growth rate (CAGR) of XX%. The expansion during the forecast period is linked to increased governmental backing, a greater emphasis on preventive healthcare, efforts to counter vaccine reluctance, improvements in healthcare systems, and escalating income in developing economies. Key trends for the forecast period encompass the incorporation of telehealth for vaccination consultations, investments in cold chain logistics, the application of artificial intelligence in vaccine development, governmental vaccination incentives and cooperation with tech firms.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19861&type=smp
Which Primay Drivers Are Accelerating Growth in the Afluria Market?
An increased occurrence of influenza, also known commonly as the flu, is predicted to bolster the growth of the Afluria market. The flu, a contagious respiratory illness brought on by influenza viruses, can cause mild to severe symptoms from fever, coughing, body aches, sore throat, and tiredness. The escalating cases of influenza can be attributed to the public’s heightened awareness of the illness, an increase in mutating viruses, and an increase in the demand for vaccinations – particularly among the elderly who are more susceptible to the disease. Afluria serves as a preventative measure against the flu by prompting the immune system to generate antibodies to combat the virus. According to data from the UK Health Security Agency published in November 2024, flu positivity increased to 2.3% in the 41st week, a jump from the previous week’s 2%. The highest rates of positivity were seen in people aged 5 to 14 years with 5.1%. This rising flu prevalence is thus boosting the afluria market’s growth. The ascension of the older population is also anticipated to boost the afluria market in the future. Falling fertility rates and longer life expectancy have resulted in the growth of the geriatric population, typically those aged 65 or above with unique health concerns brought on by age. Since this group is particularly susceptible to severe illness and death due to the flu, they require effective vaccines like Afluria to safeguard their health and minimize flu-related complications. A July 2024 report from the House of Commons Library states that the UK’s aging population, with approximately 12.7 million people aged 65 and over making up 19% of the total population in 2022, is expected to surge to 22.1 million by 2072, accounting for 27% of the population. This rise in the elderly population is driving the afluria market’s growth.
Which Primary Segments of the Afluria Market Are Driving Growth and Industry Transformations?
The afluriamarket covered in this report is segmented –
1) By Formulation: Pre-Filled Syringes; Multi-Dose Vials
2) By Clinical Indication: Influenza Prevention
3) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Government Supplier
4) By End Users: Pediatric; Adult; Geriatric
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=19861&type=smp
Which Regions Are Key Players in the Growth of the Afluria Market?
North America was the largest region in the afluria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afluria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Afluria Industry Dynamics?
The prevailing tendency in the afluria market centers on the development of advanced solutions like nano-sized particle-based vaccines to reinforce vaccine effectiveness, stability, and direct delivery. Nanoparticle-based vaccines employ minute particles, generally within the nanometer range, to deliver antigens more effectively and augment the immune response. For instance, in March 2024, Indian pharmaceutical company Cadila Pharmaceuticals Ltd., introduced the Cadiflu Tetra Vaccine, a superior quadrivalent influenza vaccine designed to avert seasonal influenza. It specifically targets four strains of the influenza virus, namely subtypes A and B, yielding wider protection during flu epidemics. The vaccine merges crucial proteins such as hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) in a single formulation, resulting in a high-quality vaccine with an improved safety profile in comparison to conventional vaccines.
View the full report here:
https://www.thebusinessresearchcompany.com/report/afluria-global-market-report
What Parameters Are Used to Define the Afluria Market?
Afluria is an inactivated influenza vaccine designed to protect against infections caused by specific strains of the influenza virus. Approved for individuals aged 6 months and older, it is administered via injection and helps stimulate the immune system to produce antibodies. Annual vaccination is recommended to ensure effective protection against seasonal flu outbreaks.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19861
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
